Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1682-1687

  Steiner, Manuel ^a,b   Hochreiter, Daniela ^a   Kasper, David C ^b   Kornmüller, Rosa ^a   Pichler, Herbert ^a   Haas, Oskar A ^a   Pötschger, Ulrike ^c   Hutter, Caroline ^a   Dworzak, Michael N ^a   Mann, Georg ^a   Attarbaschi, Andishe ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

asparaginase; Leukemia; mesenchymal cells; resistance mechanisms

Indexed keywords

ASPARAGINASE; ASPARAGINE; ASPARTIC ACID; CORTICOSTEROID; DAUNORUBICIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; AUSTRIA; BLOOD; BLOOD ANALYSIS; BONE MARROW; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; ASPARTIC ACID; BONE MARROW; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84865045235     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.668681     Document Type: Article

References (21)

1. A ppel IM, Kazemier KM, Boos J, et a l. Pharmacokinetic, pharmacodynamic and intracellular eff ects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia:results from a single agent window study. Leukemia 2008;22:1665-1679.
2. K aspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-2729.
3. S ilverman LB, Gelber RD, Dalton VK, et a l. Improved outcome for children with acute lymphoblastic leukemia:results of Dana-Farber Consortium Protocol 91 - 01. Blood 2001;97:1211-1218.
4. A sselin BL, Kreissman S, Coppola DJ, et al. Prognostic signifi cance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21:6-12.
5. A sselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989;49:4363-4368.
6. B ussolati O, Belletti S, Uggeri J, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995;220:283-291.
7. H askell CM, Canellos GP. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 1969;18: 2578-2580.
8. Kiriyama Y, Kubota M, Takimoto T, et a l. Biochemical characterization of U937 cells resistant to L-asparaginase: The role of asparagine synthetase. Leukemia 1989;3:294-297.
9. A ppel IM, den Boer ML, Meijerink JP, et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006;107:4244-4249.
10. F ine BM, Kaspers GJ, Ho M, et a l. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-299.
11. Holleman A, Cheok MH, den Boer ML, et a l. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-542.
12. I wamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-1057.
13. v an der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classifi cation, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the BFM Family Cooperative Group. Med Pediatr Oncol 1992;20: 497-505.
14. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91: 24-31.
15. Pinheiro JP, Boos J. Th e best way to use asparaginase in childhood acute lymphatic leukaemia-still to be defi ned? Br J Haematol 2004;125:117-127.
16. Riccardi R, Holcenberg JS, Glaubiger DL et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fl uid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558.
17. F ung KL, Liang RH, Chan GC. Vincristine but not imatinib could suppress mesenchymal niches support to lymphoid leukemic cells. Leuk Lymphoma 2010;51:515-522.
18. Lepage N, McDonald N, Dallaire L, et a l. Age-specifi c distribution of plasma amino acid concentrations in a healthy pediatric population. Clin Chem 1997;43:2397-2402.
19. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet 2005;44: 367-393.
20. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in fi rst bone marrow relapse: A Childrens Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141-146.
21. Panosyan EH, Grigoryan RS, Avaramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004;24: 1121-1126